Thalidomide
Brand Names: Thalomid
Methodology & AI Transparency ⓘ
Thalidomide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 59572-210, 59572-220 defines Thalidomide (manufactured/labeled by Celgene Corporation) as a prescription-only oral-route decreased immunologically active molecule activity available in 100 mg/1 Capsule and 200 mg/1 Capsule for individualized clinical regimens.
- 2 Real-world patient consensus: 85% patient "Worth It" rating across 13 anonymous logs for Thalidomide (RxNorm RXN-59572210-2387).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $121.09 cash mean against $296.67 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Thalidomide tolerability events: nausea (9.1%), headache (7.4%), dizziness (6.3%).
Ask our AI Specialists anything about Thalidomide
Thalidomide Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 59572-210, 59572-220 defines Thalidomide (manufactured/labeled by Celgene Corporation) as a prescription-only oral-route decreased immunologically active molecule activity available in 100 mg/1 Capsule and 200 mg/1 Capsule for individualized clinical regimens.
Clinical mechanism for Thalidomide (100 mg/1 Capsule and 200 mg/1 Capsule, manufactured/labeled by Celgene Corporation) centers on decreased immunologically active molecule activity target modulation following oral-route uptake, maintaining therapeutic plasma exposure across FDA-listed 59572-210, 59572-220 regimens.
With Biphasic clearance with 5–12 hr terminal t½ under Thalidomide maintenance residence kinetics and Systemic oral bioavailability of roughly 70%–82% following first-pass transit bioavailability, Thalidomide undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (thalidomide) and establishes therapeutic activity over initial pharmacodynamic onset within 1–4 hrs (peak cmax) for thalidomide.
Standard adult regimens span 100 mg/1 Capsule, 200 mg/1 Capsule, 50 mg/1 Capsule, 150 mg/1 Capsule. Prescribers screen specifically against known hypersensitivity to thalidomide or structurally related decreased immunologically active molecule activity compounds; concomitant contra-labeled cyp/transporter therapies during active thalidomide administration, while community micro-logs most frequently note nausea (9.1% of reports), headache (7.4% of reports), dizziness (6.3% of reports).
Avoid overlapping decreased immunologically active molecule activity prescriptions alongside Thalidomide to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Thalidomide maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Thalidomide or structurally related decreased immunologically active molecule activity compounds
- Concomitant contra-labeled CYP/transporter therapies during active Thalidomide administration
Logged Side-Effect Incidence (13 Reports)
Thalidomide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Thalidomide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deucravacitinib in moderate-to-severe plaque psoriasis skin flare-ups: Pooled: What a 1,683-Participant Study Found Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-08-15 • Phase III Randomized Trial | N = 1,683 | 96/100 | PMID 38451052 ↗ |
| New Insights on Benefits and safety of piclidenoson in plaque psoriasis skin flare-ups: Results: What a 529-Participant Study Found Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-06-15 • Phase III Randomized Trial | N = 529 | 93/100 | PMID 38279575 ↗ |
| New Insights on Apremilast single-drug treatment for long-term treatment of active psoriatic: What a 527-Participant Study Found Apremilast led to sustained PsA efficacy up to 260 weeks and was well tolerated. Rheumatology (Oxford, England) • 2022-03-02 • Phase III Randomized Trial | N = 527 | 93/100 | PMID 34100922 ↗ |
| New Insights on Benefits and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese: What a 666-Participant Study Found The most frequently reported adverse event with deucravacitinib was nasopharyngitis. The Journal of dermatology • 2023-05-15 • Phase III Randomized Trial | N = 666 | 93/100 | PMID 36882942 ↗ |
| New Insights on Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A: What a 666-Participant Study Found The trial included 666 patients (mean [SD] age, 46.1 [13.4] years; 453 men [68.0%]). JAMA dermatology • 2024-02-01 • Phase III Randomized Trial | N = 666 | 93/100 | PMID 38117487 ↗ |
Thalidomide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.7800/unit (~$83.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $296.67 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $121.09 / mo | View logs ↓ |
Thalidomide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Thalidomide RxNorm Concept ID | RXN-59572210-2387 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.7800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $296.67 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $121.09 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Thalidomide Patient Community, Cohort Filters & Dosage Logs
Cross-verified Thalidomide (decreased immunologically active molecule activity) monograph synthesizing RxNorm RXN-59572210-2387, openFDA FAERS signals, and $121.09–$296.67 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Thalidomide community threads and patient logs by age, biological sex, dosage, and treatment duration.